Back to Search Start Over

The effect of chemotherapy regimens in male germ cell tumors on the development of primary hypogonadism.

The effect of chemotherapy regimens in male germ cell tumors on the development of primary hypogonadism.

Authors :
Handke A
Bargen MG
Isgandarov A
Al Nader M
Krafft U
Darr C
Hadaschik B
Grünwald V
Püllen L
Source :
Scientific reports [Sci Rep] 2024 Nov 15; Vol. 14 (1), pp. 28141. Date of Electronic Publication: 2024 Nov 15.
Publication Year :
2024

Abstract

Male germ cell tumors (GCT) have excellent survival. Long-term sequelae in cancer survivors are an evolving field. We evaluated the risk of patients with GCT to develop primary hypogonadism and adherence to guideline-recommended therapy in a real-world cohort. Monocentric study at a tertiary cancer centre to evaluate treated GCT-patients (2001-2019). Post therapeutic male endocrine function, International Index of Erectile Function (IIEF)-5 and The aging males' symptoms rating scale (AMS) questionnaires were assessed. The overall response rates were low, with 44 of 402 contacted patients participating in the study. From these, 32(73%) underwent blood analysis, 42(95%) answered the IIEF-5 and 43(98%) the AMS. Latent hypogonadism (serum testosterone 8-12 nmol/l) was found in n = 9 (28%) and manifest hypogonadism (testosterone < 8 nmol/l) in n = 8 (25%). 50% (n = 21) indicated erectile dysfunction on IIEF-5 (cut off ≤ 21 pts.) and 62.8% (n = 27) reported symptomatic affection on AMS (cut off ≥ 27 pts.). Majority of tested patients revealed different degrees of hypogonadism. Standard instruments were able to detect gonadal damage in > 50%, which underscored the clinical need to evaluate endocrine function in cancer survivors. We further indicated the difficulties of today's research and provided starting points to assess barriers for study participations.<br />Competing Interests: Competing interests CD has advisory roles for Janssen and IPSEN and has received travel compensation from Janssen, IPSEN and BayerB.H. has had advisory roles for ABX, AAA/Novartis, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, AAA/Novartis, German Research Foundation, Janssen R&D, and Pfizer; and has received compensation for travel from Astellas, AstraZeneca, Bayer and Janssen R&D. A.H, MGvB, AI, MN, UK, LP declare no conflicts of interest.VG: receiving grant support, lecture fees, consulting fees, and travel support from AstraZeneca, BMS, Ipsen, and Pfizer, consulting fees and travel support from Bayer, grant support, lecture fees, and consulting fees from MSD, consulting fees from Roche, Eli Lilly, Onkowissen, and EUSA Pharma, consulting fees and lecture fees from Janssen– Cilag, PharmaMar, Merck Serono, and Eisai, lecture fees from Asklepios Clinic, Diakonie Clinic, Dortmund Hospital, andClinic of Oldenburg, and grant support and consulting fees from Novartis. Ethical approval This study protocol was reviewed and approved by the local ethics committee of University Duisburg-Essen (21-9860-BO) and conducted in accordance with the ethical standards of the Declaration of Helsinki. The participants provided informed written consent before participating in the study.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2045-2322
Volume :
14
Issue :
1
Database :
MEDLINE
Journal :
Scientific reports
Publication Type :
Academic Journal
Accession number :
39548170
Full Text :
https://doi.org/10.1038/s41598-024-78765-w